• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prevalence and risk factors of left atrial thrombus in patients with atrial fibrillation and lower class (IIa) recommendation to anticoagulants.心房颤动患者左心房血栓的患病率及危险因素与抗凝治疗的Ⅱa类推荐
Cardiovasc Diagn Ther. 2020 Aug;10(4):717-724. doi: 10.21037/cdt-20-151.
2
Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?CHA2DS2-VASc评分能否充分预测接受非维生素K口服抗凝剂治疗的已确诊房颤患者左心耳血栓形成的风险?
Medicine (Baltimore). 2020 Jun 19;99(25):e20570. doi: 10.1097/MD.0000000000020570.
3
Thrombus in the left atrial appendage in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants in clinical practice-A multicenter registry.临床实践中接受非维生素K拮抗剂口服抗凝剂治疗的房颤患者左心耳血栓——一项多中心注册研究
J Cardiovasc Electrophysiol. 2020 Aug;31(8):2005-2012. doi: 10.1111/jce.14589. Epub 2020 Jun 11.
4
Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban.房颤患者在接受电复律或导管消融术时,尽管持续使用非维生素K拮抗剂口服抗凝药治疗,仍发生左心耳血栓形成:达比加群与利伐沙班的比较
Cardiol Res Pract. 2020 Sep 17;2020:1206402. doi: 10.1155/2020/1206402. eCollection 2020.
5
Left Ventricular Ejection Fraction Is Associated with the Risk of Thrombus in the Left Atrial Appendage in Patients with Atrial Fibrillation.左心室射血分数与房颤患者左心耳血栓形成的风险相关。
Cardiovasc Ther. 2020 Apr 24;2020:3501749. doi: 10.1155/2020/3501749. eCollection 2020.
6
Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: An approach towards an individualized use of transesophageal echocardiography.心房颤动导管消融术前左心耳血栓患者的风险分层:一种个体化使用经食管超声心动图的方法。
J Cardiovasc Electrophysiol. 2017 Oct;28(10):1127-1136. doi: 10.1111/jce.13279. Epub 2017 Jul 26.
7
Prevalence of left atrial appendage thrombus detected by transoesophageal echocardiography before catheter ablation of atrial fibrillation in patients anticoagulated with non-vitamin K antagonist oral anticoagulants.非维生素 K 拮抗剂口服抗凝剂抗凝治疗的心房颤动患者行导管消融术前经食管超声心动图检测左心耳血栓的发生率。
Europace. 2019 Jan 1;21(1):48-53. doi: 10.1093/europace/euy129.
8
Risk factors of left atrial appendage thrombus in patients with non-valvular atrial fibrillation.非瓣膜性心房颤动患者左心耳血栓形成的危险因素
Open Med (Wars). 2021 Mar 3;16(1):361-366. doi: 10.1515/med-2021-0009. eCollection 2021.
9
Predictors of left atrial appendage thrombus despite NOAC use in nonvalvular atrial fibrillation and flutter.非瓣膜性心房颤动和心房扑动患者使用新型口服抗凝药(NOAC)后左心耳血栓的预测因素
Int J Cardiol. 2020 Oct 15;317:86-90. doi: 10.1016/j.ijcard.2020.04.070. Epub 2020 Apr 25.
10
Real-Time Pathophysiologic Correlates of Left Atrial Appendage Thrombus in Patients Who Underwent Transesophageal-Guided Electrical Cardioversion for Atrial Fibrillation.接受经食管引导的房颤电复律患者左心耳血栓的实时病理生理相关性
Am J Cardiol. 2018 Jun 15;121(12):1540-1547. doi: 10.1016/j.amjcard.2018.02.044. Epub 2018 Mar 13.

引用本文的文献

1
Investigating the combinatorial effects of radiofrequency ablation and anticoagulants in patients with atrial fibrillation and left atrial appendage thrombosis after successful thrombolysis.研究射频消融与抗凝剂对成功溶栓后房颤合并左心耳血栓患者的联合作用。
Exp Ther Med. 2024 Aug 23;28(5):407. doi: 10.3892/etm.2024.12696. eCollection 2024 Nov.
2
Echocardiographic assessment of left atrial appendage morphology and function-an expert proposal by the German Working Group of Cardiovascular Ultrasound.左心耳形态和功能的超声心动图评估——德国心血管超声工作组的专家建议
Clin Res Cardiol. 2025 Jan;114(1):25-40. doi: 10.1007/s00392-024-02492-5. Epub 2024 Aug 28.
3
The risk factors of thrombus formation and the effect of catheter ablation on repetitive thrombus formation in patients with atrial fibrillation: a single center retrospective study in China.在中国的一个单中心回顾性研究中,探讨了房颤患者血栓形成的危险因素和导管消融对反复血栓形成的影响。
BMC Cardiovasc Disord. 2023 Jan 17;23(1):28. doi: 10.1186/s12872-023-03050-z.
4
Risk factors for left atrial thrombus in younger patients (aged < 65 years) with atrial fibrillation or atrial flutter: Data from the multicenter left atrial thrombus on transesophageal echocardiography (LATTEE) registry.年龄小于65岁的房颤或房扑年轻患者左心房血栓形成的危险因素:来自多中心经食管超声心动图左心房血栓(LATTEE)注册研究的数据。
Front Cardiovasc Med. 2022 Oct 12;9:973043. doi: 10.3389/fcvm.2022.973043. eCollection 2022.
5
Left Atrial Appendage Depth and Tachycardia Bradycardia Syndrome as Important Predictors of Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation.左心耳深度和快慢综合征是预测非瓣膜性心房颤动患者左心耳血栓的重要指标。
Comput Math Methods Med. 2022 Mar 30;2022:4632823. doi: 10.1155/2022/4632823. eCollection 2022.
6
Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, including compliance with current guidelines-data from the POLish Atrial Fibrillation (POL-AF) Registry.接受经皮冠状动脉介入治疗的心房颤动患者的抗栓治疗,包括遵循现行指南——来自波兰心房颤动(POL-AF)注册研究的数据
Cardiovasc Diagn Ther. 2021 Feb;11(1):14-27. doi: 10.21037/cdt-20-839.

本文引用的文献

1
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.非维生素K拮抗剂口服抗凝药用于房颤患者预防继发性卒中及全身性栓塞
Cardiol J. 2021;28(6):896-904. doi: 10.5603/CJ.a2019.0069. Epub 2019 Jul 17.
2
Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus.心房颤动类型和肾功能不全是左心房血栓的重要预测因素。
Heart. 2019 Sep;105(17):1310-1315. doi: 10.1136/heartjnl-2018-314492. Epub 2019 Apr 30.
3
Prevalence of left atrial appendage thrombus detected by transoesophageal echocardiography before catheter ablation of atrial fibrillation in patients anticoagulated with non-vitamin K antagonist oral anticoagulants.非维生素 K 拮抗剂口服抗凝剂抗凝治疗的心房颤动患者行导管消融术前经食管超声心动图检测左心耳血栓的发生率。
Europace. 2019 Jan 1;21(1):48-53. doi: 10.1093/europace/euy129.
4
NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world.NOACs 和心房颤动:真实世界中左心房血栓形成的发生率及预测因素。
Int J Cardiol. 2017 Dec 15;249:179-183. doi: 10.1016/j.ijcard.2017.07.048.
5
CHADS-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study.用于识别真正低风险房颤卒中的CHADS-VASc评分:一项韩国全国性队列研究
Stroke. 2017 Nov;48(11):2984-2990. doi: 10.1161/STROKEAHA.117.018551. Epub 2017 Sep 22.
6
Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation.在房颤导管消融术前接受非维生素K口服抗凝剂与华法林治疗的患者中左心耳血栓的发生率及预测因素
Am J Cardiol. 2017 Apr 1;119(7):1017-1022. doi: 10.1016/j.amjcard.2016.12.008. Epub 2017 Jan 5.
7
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
8
Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?对于 CHA2DS2-VASc 评分(除性别以外)有 1 个额外危险因素的房颤患者,是否应接受口服抗凝治疗?
J Am Coll Cardiol. 2015 Feb 24;65(7):635-42. doi: 10.1016/j.jacc.2014.11.046.
9
Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry).欧洲心脏病专家对心房颤动患者的预后和治疗:EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase(EORP-AF Pilot 注册研究)的一年随访结果。
Eur Heart J. 2014 Dec 14;35(47):3365-76. doi: 10.1093/eurheartj/ehu374. Epub 2014 Aug 31.
10
Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?心房颤动的当代管理:临床注册研究能告诉我们哪些关于卒中预防和当前治疗方法的信息?
J Am Heart Assoc. 2014 Aug 27;3(4):e001179. doi: 10.1161/JAHA.114.001179.

心房颤动患者左心房血栓的患病率及危险因素与抗凝治疗的Ⅱa类推荐

Prevalence and risk factors of left atrial thrombus in patients with atrial fibrillation and lower class (IIa) recommendation to anticoagulants.

作者信息

Uziębło-Życzkowska Beata, Krzesiński Paweł, Jurek Agnieszka, Budnik Monika, Gorczyca Iwona, Kapłon-Cieślicka Agnieszka, Kiliszek Marek, Wójcik Agnieszka, Gawałko Monika, Jelonek Olga, Michalska Anna, Starzyk Katarzyna, Scisło Piotr, Kochanowski Janusz, Filipiak Krzysztof J, Wożakowska-Kapłon Beata, Opolski Grzegorz, Gielerak Grzegorz

机构信息

Department of Cardiology and Internal Diseases, Military Institute of Medicine, Warsaw, Poland.

1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

出版信息

Cardiovasc Diagn Ther. 2020 Aug;10(4):717-724. doi: 10.21037/cdt-20-151.

DOI:10.21037/cdt-20-151
PMID:32968628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7487402/
Abstract

BACKGROUND

Oral anticoagulation therapy (OAT) prevents ischaemic incidents in patients with atrial fibrillation (AF). CHADS-VASc risk score of ≥2 points in men and ≥3 in women is a class I indication for OAT. OAT should also be considered as a prevention of thromboembolism in AF men with a CHADS-VASc score of 1 point and women with 2 points, but the class of recommendation is lower (IIa). This study aims to assess the occurrence of left atrial appendage thrombus (LAAT) and risk factors of its formation in patients with lower class recommendation to oral antiocoagulation treatment.

METHODS

The study group consisted of 1,858 patients: 555 patients with class IIa indication to OAT (IIa group) and 1,303 patients with class I indication as a control group (I group). Patients were admitted to three cardiology departments. All subjects underwent transoesophageal echocardiography.

RESULTS

The incidence of LAAT was comparable in both IIa and I group: LAAT was confirmed in 30 (5.4%) subjects of IIa group and in 77 (5.9%) of I group. The prevalence of LAAT in IIa group was higher on treatment with VKAs (in comparison to NOACs) (8.4% 3.4%, P=0.010), and lower in case of paroxysmal AF (in comparison to non-paroxysmal AF) (2.4% 9.8%, P=0.0002). Multivariate logistic regression revealed the following variables as the independent predictors of LAAT in IIa group: treatment with VKAs (OR 2.99, 95% CI: 1.33-6.69; P=0.007), paroxysmal AF (OR 0.26, 95% CI: 0.11-0.62; P=0.002) and eGFR <60 mL/min/1.73 m (OR 3.19, 95% CI: 1.42-7.16; P=0.005).

CONCLUSIONS

The prevalence of LAAT in AF patients with lower class (IIa) recommendation to anticoagulants was comparable to higher (I). Treatment with VKAs, along with non-paroxysmal type of AF and eGFR <60 mL/min/1.72 m were identified as the strongest predictors of LAAT in IIa group.

摘要

背景

口服抗凝治疗(OAT)可预防心房颤动(AF)患者发生缺血性事件。男性CHADS-VASc风险评分≥2分且女性≥3分是OAT的I类适应证。对于CHADS-VASc评分为1分的AF男性患者和2分的女性患者,OAT也应被视为预防血栓栓塞的措施,但推荐等级较低(IIa类)。本研究旨在评估口服抗凝治疗推荐等级较低的患者左心耳血栓(LAAT)的发生率及其形成的危险因素。

方法

研究组由1858例患者组成:555例有OAT IIa类适应证的患者(IIa组)和1303例有I类适应证的患者作为对照组(I组)。患者被收治于三个心内科。所有受试者均接受经食管超声心动图检查。

结果

IIa组和I组LAAT的发生率相当:IIa组30例(5.4%)受试者和I组77例(5.9%)受试者确诊有LAAT。IIa组中使用维生素K拮抗剂(VKA)治疗时LAAT的患病率较高(与非维生素K拮抗剂类口服抗凝药[NOACs]相比)(8.4%对3.4%,P = 0.010),而阵发性AF患者中LAAT的患病率较低(与非阵发性AF相比)(2.4%对9.8%,P = 0.0002)。多因素逻辑回归显示,以下变量是IIa组LAAT的独立预测因素:使用VKA治疗(比值比[OR]2.99,95%置信区间[CI]:1.33 - 6.69;P = 0.007)、阵发性AF(OR 0.26,95%CI:0.11 - 0.62;P = 0.002)和估算肾小球滤过率(eGFR)<60 mL/min/1.73 m²(OR